Trials / Completed

CompletedNCT00144586

Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 42 (actual)

Sponsor: Chugai Pharmaceutical · Industry
Sex: All
Age: 20 Years – 75 Years
Healthy volunteers: Not accepted

Summary

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.

Conditions

Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	MRA(Tocilizumab)	8mg/kg/4 weeks

Timeline

Start date: 2005-03-01
Primary completion: 2008-08-01
Completion: 2009-06-01
First posted: 2005-09-05
Last updated: 2013-08-09

Source: ClinicalTrials.gov record NCT00144586. Inclusion in this directory is not an endorsement.